Bridging from Intramuscular to Limb Perfusion Delivery of rAAV: Optimization in a Non-human Primate Study

Phase 1 and phase 2 gene therapy trials using intramuscular (IM) administration of a recombinant adeno-associated virus serotype 1 (rAAV1) for replacement of serum alpha-1 antitrypsin (AAT) deficiency have shown long-term (5-year) stable transgene expression at approximately 2% to 3% of therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gruntman, Alisha M., Gernoux, Gwladys, Tang, Qiushi, Ye, Guo-Jie, Knop, Dave R., Wang, Gensheng, Benson, Janet, Coleman, Kristen E., Keeler, Allison M., Mueller, Christian, Chicoine, Louis G., Chulay, Jeffrey D., Flotte, Terence R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383191/
https://www.ncbi.nlm.nih.gov/pubmed/30828586
http://dx.doi.org/10.1016/j.omtm.2019.01.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383191/
https://www.ncbi.nlm.nih.gov/pubmed/30828586
http://dx.doi.org/10.1016/j.omtm.2019.01.013

Ejemplares similares